UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2012-04, Vol.379 (9824), p.1403-1411

2012

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers

Journal of clinical pharmacology, 2012-07, Vol.52 (7), p.1007-1016

2012

Volltextzugriff (PDF)

Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies

Clinical and translational science, 2024-03, Vol.17 (3), p.e13722-n/a

2024

Volltextzugriff (PDF)

A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides

Frontiers in physiology, 2023-06, Vol.14, p.1130925-1130925

2023

Volltextzugriff (PDF)

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury

Toxicological sciences, 2017-05, Vol.157 (1), p.50-61

2017

Volltextzugriff (PDF)

Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Clinical and translational science, 2023-07, Vol.16 (7), p.1149-1162

2023

Volltextzugriff (PDF)

Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques

Clinical and translational science, 2019-09, Vol.12 (5), p.519-528

2019

Volltextzugriff (PDF)

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development

Clinical and translational science, 2022-04, Vol.15 (4), p.1003-1013

2022

Volltextzugriff (PDF)

Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

Clinical and translational science, 2022-06, Vol.15 (6), p.1430-1438

2022

Volltextzugriff (PDF)

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials

Clinical and translational science, 2021-09, Vol.14 (5), p.1864-1874

2021

Volltextzugriff (PDF)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis

PloS one, 2013-06, Vol.8 (6), p.e66422

2013

Volltextzugriff (PDF)

Mathematical Models for Early Detection of Relapse in Multiple Myeloma Patients Treated with Bortezomib/Lenalidomide/Dexamethasone

Blood, 2022-11, Vol.140 (Supplement 1), p.4310-4311

2022

Volltextzugriff (PDF)

Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure

Clinical pharmacology and therapeutics, 2021-06, Vol.109 (6), p.1583-1592

2021

Volltextzugriff (PDF)

Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin

British journal of clinical pharmacology, 2016-04, Vol.81 (4), p.700-712

2016

Volltextzugriff (PDF)

A Population Pharmacokinetic (Pk)- Pharmacodynamic (Pd) Analysis Of Peginesatide India Lysis Patients With Chronic Kidney Disease

Kidney research and clinical practice, 2012-06, Vol.31 (2), p.A60-A60

2012

Volltextzugriff (PDF)

A Quantitative Systems Pharmacology Model Describing the Cellular Kinetic‐Pharmacodynamic Relationship for a Live Biotherapeutic Product to Support Microbiome Drug Development

Clinical pharmacology and therapeutics, 2023-09, Vol.114 (3), p.633-643

2023

Volltextzugriff (PDF)

Population pharmacokinetics, enzyme occupancy, and 24 S ‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Clinical and translational science, 2023-07, Vol.16 (7), p.1149-1162

2023

Volltextzugriff (PDF)

Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling

Journal of pharmacokinetics and pharmacodynamics, 2019-02, Vol.46 (1), p.15-25

2019

Volltextzugriff (PDF)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Drugs in R&D, 2018-06, Vol.18 (2), p.109-118

2018

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension

Journal of clinical pharmacology, 2016-08, Vol.56 (8), p.988-998

2016

Volltextzugriff (PDF)

A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder

Basic & clinical pharmacology & toxicology, 2016-05, Vol.118 (5), p.344-355

2016

Volltextzugriff (PDF)

Model‐Based Approach to Predict Adherence to Protocol During Antiobesity Trials

Journal of clinical pharmacology, 2018-02, Vol.58 (2), p.240-253

2018

Volltextzugriff (PDF)

A quantitative systems pharmacology model of colonic motility with applications in drug development

Journal of pharmacokinetics and pharmacodynamics, 2019-10, Vol.46 (5), p.485-498

2019

Volltextzugriff (PDF)

Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methylcellulose matrices

Pharmaceutical research, 1993-11, Vol.10 (11), p.1648

1993

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers

Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies

A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury

Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development

Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis

Mathematical Models for Early Detection of Relapse in Multiple Myeloma Patients Treated with Bortezomib/Lenalidomide/Dexamethasone

Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure

Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin

A Population Pharmacokinetic (Pk)- Pharmacodynamic (Pd) Analysis Of Peginesatide India Lysis Patients With Chronic Kidney Disease

A Quantitative Systems Pharmacology Model Describing the Cellular Kinetic‐Pharmacodynamic Relationship for a Live Biotherapeutic Product to Support Microbiome Drug Development

Population pharmacokinetics, enzyme occupancy, and 24 S ‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension

A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder

Model‐Based Approach to Predict Adherence to Protocol During Antiobesity Trials

A quantitative systems pharmacology model of colonic motility with applications in drug development

Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methylcellulose matrices

Suchergebnisse filtern